CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 143 enrolled
Drug / intervention
Bupropion +1 moredrug
Likely dose
Bupropion 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00304707
NCT00304707Phase 3Completed
CompareCT.gov

Bupropion Treatment for Smokers in Recovery

National Institute on Drug Abuse (NIDA)·interventional·Posted Mar 20, 2006·Updated May 15, 2017

In Brief

A Phase 3 clinical trial evaluating Bupropion and placebo for Smoking Cessation and Alcohol-Related Disorders. Completed, enrolled 143 participants across 1 site.

Detailed Summary

Smoking is often a problem for alcohol dependent individuals. Many people who seek treatment for alcohol dependence are unable to quit smoking. The purpose of this study is to evaluate the effectiveness of bupropion, an antidepressant medication, in treating smokers receiving treatment for alcohol dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation, Alcohol-Related Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 20, 2006
Enrollment StartApr 1, 2005
Primary CompletionFeb 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.3 years ago

Interventions

Bupropiondrug

300 mg QD

placebodrug

placebo